Investor Relations

Print   Email  
Stock price graph

Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.

View all »   RSSRecent Releases

Dec 3, 2014
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer

Nov 13, 2014
Ocera Reports Third Quarter 2014 Financial Results

View all »Events & Presentations

Mar 2, 2015 at 4:50 PM ET
Cowen and Company Annual Health Care Conference